Table 1.
The correlations between BRMS1 expression and the clinicopathological characteristics of nasopharyngeal carcinoma
|
Characteristic |
Training set (n=120) |
Testing set (n=154) |
Overall patients (n=274) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| |
low |
high |
P* |
low |
high |
P* |
low |
high |
P* |
| |
expression |
expression |
|
expression |
expression |
|
expression |
expression |
|
| no. (%) | no. (%) | no. (%) | no. (%) | no. (%) | no. (%) | ||||
| Gender |
|
|
|
|
|
|
|
|
|
| Male |
28 (66.7) |
60 (76.9) |
0.226 |
44 (77.2) |
74 (76.3) |
0.898 |
72 (72.7) |
134 (76.6) |
0.286 |
| Female |
14 (33.3) |
18 (23.1) |
|
13 (22.8) |
23 (23.7) |
|
27 (27.3) |
41 (23.4) |
|
| Age (years) |
|
|
|
|
|
|
|
|
|
| ≤ 46 |
20 (47.6) |
37 (47.4) |
0.985 |
31 (54.4) |
49 (50.5) |
0.643 |
51 (51.5) |
86 (49.1) |
0.401 |
| > 46 |
22 (52.4) |
41 (52.6) |
|
26 (45.6) |
48 (49.5) |
|
48 (49.5) |
89 (50.9) |
|
| WHO type |
|
|
|
|
|
|
|
|
|
| Type III |
40 (95.2) |
74 (94.9) |
1.000 |
56 (98.2) |
94 (96.9) |
1.000 |
96 (97.0) |
168 (96.0) |
0.482 |
| Other type |
2 (4.8) |
4 (5.1) |
|
1 (1.8) |
3 (3.1) |
|
3 (3.0) |
7 (4.0) |
|
| VCA-IgA |
|
|
|
|
|
|
|
|
|
| ≥ 1:320 |
23(54.8) |
41(52.6) |
0.818 |
28(49.1) |
48(49.5) |
0.965 |
51(51.5) |
89(50.9) |
0.917 |
| < 1:320 |
19(45.2) |
37(47.4) |
|
29(50.9) |
49(50.5) |
|
48(48.5) |
86(49.1) |
|
| EA-IgA |
|
|
|
|
|
|
|
|
|
| ≥ 1:20 |
20(47.6) |
43(55.1) |
0.432 |
33(57.9) |
50(51.5) |
0.445 |
53(53.5) |
93(53.1) |
0.950 |
| < 1:20 |
22(52.4) |
35(44.9) |
|
24(42.1) |
47(48.5) |
|
46(46.7) |
82(46.9) |
|
| AER |
|
|
|
|
|
|
|
|
|
| ≥ 63% |
8(19.0) |
23(29.5) |
0.213 |
17(29.8) |
26(26.8) |
0.687 |
25(25.3) |
49(28.0) |
0.623 |
| < 63% |
34(81.0) |
55(70.5) |
|
40(70.2) |
71(73.2) |
|
74(74.7) |
126(72.0) |
|
| UICC 7th T stage |
|
|
|
|
|
|
|
|
|
| T1 |
5 (11.9) |
16 (20.5) |
0.470 |
11 (19.3) |
18 (18.6) |
0.996 |
16 (16.2) |
34 (19.4) |
0.853 |
| T2 |
17 (40.5) |
22 (28.2) |
|
18 (31.6) |
32 (33.0) |
|
35 (35.4) |
54 (30.9) |
|
| T3 |
9 (21.4) |
19 (24.4) |
|
16 (28.1) |
26 (26.8) |
|
25 (25.3) |
45 (25.5) |
|
| T4 |
11 (26.2) |
21 (26.9) |
|
12 (21.1) |
21 (21.6) |
|
23 (23.2) |
42 (23.7) |
|
| UICC 7th N stage |
|
|
|
|
|
|
|
|
|
| N0 |
4 (9.5) |
14 (17.9) |
0.644 |
8 (14.0) |
14 (14.4) |
0.837 |
12 (12.1) |
28 (16.0) |
0.732 |
| N1 |
22 (52.4) |
36 (46.2) |
|
24 (42.1) |
47 (48.5) |
|
46 (46.5) |
83 (47.4) |
|
| N2 |
10 (23.8) |
16 (20.5) |
|
15 (26.3) |
20 (20.6) |
|
25 (25.3) |
36 (20.6) |
|
| N3 |
6 (14.3) |
12 (15.4) |
|
10 (17.5) |
16 (16.5) |
|
16 (16.2) |
28 (16.0) |
|
| |
|
|
|
|
|
|
|
||
| No |
4 (9.5) |
14 (17.9) |
0.307 |
8 (14.0) |
14 (14.4) |
0.806 |
12 (12.1) |
28 (16.0) |
0.382 |
| Yes |
38 (90.5) |
64 (82.1) |
|
49 (86.0) |
83 (85.6) |
|
87 (87.9) |
147 (84.0) |
|
| |
|
|
|
|
|
|
|
||
| I |
0 (0.0) |
4 (5.1) |
0.513 |
1 (1.8) |
3 (3.1) |
0.949 |
8 (2.9) |
8 (2.9) |
0.538 |
| II |
13 (31.0) |
22 (28.2) |
|
17 (29.8) |
27 (27.8) |
|
79 (28.8) |
79 (28.8) |
|
| III |
13 (31.0) |
22 (28.2) |
|
19 (33.3) |
31 (32.0) |
|
85 (31.0) |
85 (31.0) |
|
| IV |
16 (38.0) |
30 (38.5) |
|
20 (35.1) |
36 (37.1) |
|
102 (37.2) |
102 (37.2) |
|
| |
|
|
|
|
|
|
|
||
| No |
24 (57.1) |
67 (85.9) |
0.000 |
35 (61.4) |
83 (85.6) |
0.000 |
59 (59.6) |
150 (85.7) |
0.000 |
| Yes | 18 (42.8) | 11 (14.1) | 22 (38.6) | 14 (14.4) | 40 (40.4) | 25 (14.3) | |||
* p value was calculated using the chi-squared or Fisher's exact tests. #: The presence of distant metastasis on or before the last follow-up (April 30, 2011).